CAMPHealthcare · BiotechnologyThe 10 Wall Street analysts covering CAMP4 Therapeutics Corp. hold a median 12-month price target of $9 — +146.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores CAMP4 Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (90): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (18): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CAMP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +146.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Oct 2026 | Raymond James | Initiates | Strong Buy | $10 |
| 15 Oct 2026 | Needham | Initiates | Buy | $8.00 |
| 15 Oct 2026 | Needham | Initiates | Buy | — |
| 5 Oct 2026 | Oppenheimer | Initiates | Outperform | $15 |
| 5 Oct 2026 | Oppenheimer | Initiates | Outperform | — |
| 29 Sept 2026 | Chardan Capital | Maintains | Buy | $6.50 → $6.00 |
| 29 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 14 Aug 2026 | Piper Sandler | Reiterates | Overweight | $12 → $15 |
| 14 Aug 2026 | Piper Sandler | Reiterates | Overweight | — |
| 16 June 2026 | JP Morgan | Upgrade | Overweight | — |
| 16 June 2026 | JP Morgan | Upgrade | Overweight | $5.00 → $9.00 |
| 10 June 2026 | Chardan Capital | Initiates | Buy | $6.50 |
| 10 June 2026 | Chardan Capital | Initiates | Buy | — |
| 14 Apr 2026 | Rodman & Renshaw | Initiates | Buy | — |
| 2 Apr 2026 | Leerink Partners | Maintains | Outperform | — |
| 2 Oct 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 16 Sept 2025 | JP Morgan | Downgrade | Neutral | — |
| 15 Sept 2025 | Piper Sandler | Maintains | Overweight | — |
| 27 May 2025 | Wedbush | Initiates | Outperform | — |
| 5 Nov 2024 | JP Morgan | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CAMP appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, CAMP4 Therapeutics Corp. returned −6.6% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 5% of US stocks
Cheaper than 99% of US stocks
Cheaper than 76% of US stocks
Higher than 68% of US stocks
Higher than 58% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CAMP4 Therapeutics Corp. has a market value of $229.0M and an enterprise value of $145.0M.
Revenue in the twelve months to 30 June 2026: $4.2M. The latest quarter grew 18.8% year on year.
Net income over the same four quarters: −$107.2M, a −2543.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$28.7M.
Trailing P/E: −1.4×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CAMP4 Therapeutics Corp. employs 48 people — $88K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CAMP4 Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says CAMP4 Therapeutics may report negative earnings and lacks the two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report. The item offers expectations for the release.
Why it matters — CAMP watchers may want to note the cautiously framed earnings outlook ahead of the Q3 report.
CAMP4 Therapeutics received EU Clinical Trials Regulation approval for a Phase 1/2 trial of CMP-002 in patients with SYNGAP1-related disorder. The approval builds on recent clearances in the United Kingdom, Australia, and Argentina.
Why it matters — The EU approval adds to the regions cleared to initiate CAMP4’s global Phase 1/2 trial of CMP-002.
Korro and Tevard presented RNA-medicine approaches intended to expand beyond protein silencing, including programs aimed at repairing genetic defects or restoring full-length protein production.
Why it matters — The item provides context on approaches discussed at a CAMP4 conference, but does not describe a CAMP4-specific program or development.
CAMP4 Therapeutics announced it will participate in a panel at Chardan's 10th Annual Healthcare Conference on October 20, 2026.
Why it matters — CAMP watchers may note the company's scheduled participation in an upcoming healthcare conference panel.
Camp4 Therapeutics Corporation hosted an Analyst/Investor Day, and a transcript of the event has been published by Seeking Alpha. The item provides a record of the company's presentation and discussion with analysts and investors.
Why it matters — The transcript gives CAMP shareholders and observers direct access to the company's latest strategic communications from its investor-facing event.
The 10 Wall Street analysts covering CAMP4 Therapeutics Corp. have a median 12-month price target of $9, with estimates ranging from $6 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering CAMP4 Therapeutics Corp., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CAMP4 Therapeutics Corp. 56 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, CAMP4 Therapeutics Corp. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (90 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +146.6% from the last close, and Ticker Nerd's factor model ranks CAMP4 Therapeutics Corp. 56 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CAMP4 Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $15 over the next 12 months.
CAMP4 Therapeutics Corp. returned -6.6% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production.
The most recent item we track (Zacks Investment Research, 29 Oct 2026): "CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release". Zacks Investment Research says CAMP4 Therapeutics may report negative earnings and lacks the two key ingredients associated with a likely earnings beat ahead of its upcoming Q3 report. The item offers expectations for the release.
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapeutics designed to increase gene expression and restore healthy protein levels. The company applies its ASO-based approach to address the underlying causes of genetic diseases by targeting regulatory RNA and aiming for precise control of protein production. Its work centers on disease areas where insufficient protein activity plays a key role, including disorders affecting the liver and central nervous system. Camp4 Therapeutics Corporation’s current pipeline includes product candidates for urea cycle disorders and SYNGAP1-related disorders, reflecting its focus on rare and genetically driven conditions. Based in Cambridge, Massachusetts, the company operates within the biotechnology sector and contributes to the broader effort to create targeted treatments for inherited diseases through RNA modulation.
CEO Mr. Joshua Mandel-Brehm · 48 employees · United States · https://www.camp4tx.com
